EGFR
E902872
EGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase that regulates cell growth and survival and is frequently implicated in cancer development and progression.
All labels observed (2)
| Label | Occurrences |
|---|---|
| EGFR canonical | 1 |
| EGFR (ERBB1) | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074233 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: EGFR Context triple: [HER2 receptor, formsHeterodimerWith, EGFR]
-
A.
ERBB2
ERBB2, also known as HER2, is a receptor tyrosine kinase frequently overexpressed in certain breast and other cancers and serves as a key therapeutic target.
-
B.
EGF
EGF is the ICAO airline designator used to identify American Eagle Airlines in aviation operations and communications.
-
C.
HER2 receptor
The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
-
D.
EWSR1
EWSR1 is a multifunctional RNA-binding protein involved in transcriptional regulation and RNA processing, best known for its role in chromosomal translocations that drive various sarcomas and leukemias.
-
E.
CDK4
CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: EGFR Target entity description: EGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase that regulates cell growth and survival and is frequently implicated in cancer development and progression.
-
A.
ERBB2
ERBB2, also known as HER2, is a receptor tyrosine kinase frequently overexpressed in certain breast and other cancers and serves as a key therapeutic target.
-
B.
EGF
EGF is the ICAO airline designator used to identify American Eagle Airlines in aviation operations and communications.
-
C.
HER2 receptor
The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
-
D.
EWSR1
EWSR1 is a multifunctional RNA-binding protein involved in transcriptional regulation and RNA processing, best known for its role in chromosomal translocations that drive various sarcomas and leukemias.
-
E.
CDK4
CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
- F. None of above. chosen
Statements (78)
| Predicate | Object |
|---|---|
| instanceOf |
cell surface receptor
ⓘ
human gene ⓘ proto-oncogene protein ⓘ receptor tyrosine kinase ⓘ transmembrane protein ⓘ |
| activatedBy |
amphiregulin
NERFINISHED
ⓘ
betacellulin NERFINISHED ⓘ epidermal growth factor NERFINISHED ⓘ epigen ⓘ epiregulin NERFINISHED ⓘ heparin-binding EGF-like growth factor ⓘ transforming growth factor alpha NERFINISHED ⓘ |
| alsoKnownAs |
ERBB1
NERFINISHED
ⓘ
HER1 NERFINISHED ⓘ epidermal growth factor receptor tyrosine kinase NERFINISHED ⓘ |
| associatedWithDisease |
breast cancer
ⓘ
colorectal cancer ⓘ glioblastoma ⓘ head and neck squamous cell carcinoma ⓘ non-small cell lung cancer ⓘ |
| belongsToFamily | ErbB receptor family NERFINISHED ⓘ |
| biologicalProcess |
apoptotic process regulation
ⓘ
cell differentiation ⓘ regulation of cell proliferation ⓘ regulation of cell survival ⓘ signal transduction ⓘ |
| cellularComponent |
cell surface
ⓘ
endosome ⓘ plasma membrane ⓘ |
| downstreamPathway |
JAK-STAT signaling pathway
NERFINISHED
ⓘ
PI3K-AKT signaling pathway NERFINISHED ⓘ PLCγ-PKC signaling pathway ⓘ RAS-RAF-MEK-ERK signaling pathway NERFINISHED ⓘ |
| encodes | epidermal growth factor receptor protein NERFINISHED ⓘ |
| endocytosis | clathrin-mediated internalization after activation ⓘ |
| fullName | epidermal growth factor receptor NERFINISHED ⓘ |
| geneSymbol | EGFR NERFINISHED ⓘ |
| hasDomain |
extracellular ligand-binding domain
ⓘ
intracellular tyrosine kinase domain ⓘ single-pass transmembrane domain ⓘ |
| hasEntrezGeneID | 1956 ⓘ |
| hasHGNCID | HGNC:3236 ⓘ |
| hasLength | 1210 amino acids (canonical human isoform) ⓘ |
| hasUniProtID | P00533 ⓘ |
| involvedIn |
cancer development
ⓘ
cancer progression ⓘ |
| locatedAtCytogeneticBand | 7p11.2 GENERATED ⓘ |
| locatedOnChromosome | human chromosome 7 ⓘ |
| locatedOnChromosomeArm | 7p ⓘ |
| mechanismOfActivation |
autophosphorylation of tyrosine residues
ⓘ
ligand-induced receptor dimerization ⓘ |
| molecularFunction |
ATP binding
ⓘ
protein tyrosine kinase activity ⓘ transmembrane receptor activity ⓘ |
| oncogenicAlteration |
EGFRvIII deletion mutant
NERFINISHED
ⓘ
L858R point mutation in exon 21 ⓘ T790M resistance mutation ⓘ activating point mutation ⓘ exon 19 deletion mutation ⓘ extracellular domain mutation ⓘ gene amplification ⓘ |
| organism | Homo sapiens ⓘ |
| postTranslationalModification |
N-linked glycosylation
ⓘ
tyrosine phosphorylation ⓘ |
| recyclingOrDegradation | sorted to lysosomal degradation or recycled to plasma membrane ⓘ |
| regulates |
angiogenesis-related signaling
ⓘ
cell cycle progression ⓘ cell migration ⓘ |
| targetOfDrug |
afatinib
NERFINISHED
ⓘ
cetuximab ⓘ dacomitinib NERFINISHED ⓘ erlotinib NERFINISHED ⓘ gefitinib NERFINISHED ⓘ necitumumab NERFINISHED ⓘ osimertinib NERFINISHED ⓘ panitumumab NERFINISHED ⓘ |
| targetOfDrugClass |
EGFR tyrosine kinase inhibitors
ⓘ
anti-EGFR monoclonal antibodies ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: EGFR Description of subject: EGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase that regulates cell growth and survival and is frequently implicated in cancer development and progression.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.